Breakthrough in Neuroblastoma Research: Identifying Genetic Defects for Personalized Treatment

Strategic Insights -

Neuroblastoma is a complex and often unpredictable childhood cancer that affects the peripheral nervous system. A recent study by the Children's Oncology Group, published in the New England Journal of Medicine, identifies genetic defects on chromosomes 1 and 11 as significant risk factors for high-risk neuroblastoma. The research, led by Dr. John Maris of The Children's Hospital of Philadelphia, shows that loss of genetic material on these chromosomes is linked to poor prognosis and increased risk of death.

Key Takeaways:

  • Loss of genes on chromosome 1 or chromosome 11 raises the risk of death from neuroblastoma, even when other indicators suggest a lower-risk form of the disease.
  • The Children's Oncology Group's study analyzed tumor samples from 915 children with neuroblastoma and identified 1p36 and 11q23 as contributing to high-risk neuroblastoma.
  • Unbalanced 11q LOH and 1p36 LOH were independent markers of worse outcome for patients, regardless of other prognostic clues.
  • The study found that children with localized disease without MYCN amplification, who showed unbalanced 11q LOH, may benefit from more intensive early treatment such as chemotherapy.
  • The Children's Oncology Group plans to add the status of chromosome arms 1p and 11q to its list of prognostic markers in evaluating children with neuroblastoma.
  • Researchers hope to identify one or more genes on chromosome arm 11q involved in aggressive neuroblastoma and use those as targets for therapy.

Statistics:

  • Neuroblastoma is the most common cancer in infants, accounting for 10% of all pediatric cancers.
  • Survival rates for pediatric cancer have risen from roughly 25% in the 1970s to nearly 80% today.
  • High percentages of children with cancer have participated in clinical trials of new treatments.
  • One such treatment used at Children's Hospital is a compound called MIBG that selectively concentrates in neuroblastoma cells, with low toxicity to healthy tissue.

Sources:

  • New England Journal of Medicine, cited as "study from the Children's Oncology Group, a cooperative research organization of pediatric cancer centers."
  • Children's Hospital of Philadelphia, Department of Pediatrics, cited as "The Children's Hospital of Philadelphia."
  • Health & Medicine Week, cited as "Health & Medicine Week editors from staff and other reports."